Form 4: Y-mAbs Therapeutics Executive Receives Stock Options and Restricted Stock Units

John LaRocca, SVP, General Counsel & Secretary of Y-mAbs Therapeutics, was granted stock options and restricted stock units as part of the company's 2018 Equity Incentive Plan.

Summary

• John LaRocca, a senior executive at Y-mAbs Therapeutics, received 21,500 restricted stock units (RSUs) and 42,900 stock options on January 17, 2025.
• The RSUs will vest in three equal installments on January 17, 2026, 2027, and 2028, contingent on continued service.
• The stock options vest as to 25% on January 17, 2026, and then in equal monthly installments until fully vested, also contingent on continued service.
• The stock options have an exercise price of $6.16 and expire on January 17, 2035.

Sentiment

Score: 7

Explanation: The document reflects a standard compensation practice, indicating a positive but not exceptional event. The vesting schedule suggests a long-term commitment from the executive.

Positives

• The grant of stock options and RSUs aligns the executive's interests with those of the shareholders.
• The vesting schedule encourages long-term commitment from the executive.

Risks

• The vesting of the stock options and RSUs is contingent on the executive's continued service, which could be a risk if the executive leaves the company.

Industry Context

The granting of stock options and restricted stock units is a common practice in the biotechnology industry to incentivize and retain key executives.

Comparison to Industry Standards

• Stock option and RSU grants are standard practice for executive compensation in the biotech industry, similar to companies like BioMarin Pharmaceutical and Regeneron Pharmaceuticals.
• The vesting schedules are also typical, with multi-year vesting periods to encourage long-term commitment, which is similar to the vesting schedules of other biotech companies.

Stakeholder Impact

• The grant of stock options and RSUs could be viewed positively by shareholders as it aligns executive interests with company performance.
• Employees may see this as a positive sign of the company's commitment to its leadership.

Key Dates

Keywords

stock options, restricted stock units, equity incentive plan, executive compensation, vesting, Y-mAbs Therapeutics, YMAB